Importantly, lower mutation rates in two FDA‐approved therapeutic targets, namely, EGFR in lung cancer and KRAS in colorectal cancer, were identified, indicating that young patients with lung cancer or colorectal cancer may have a smaller chance of benefitting from targeted therapies. Here, KRAS is linked to lung cancer.